Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy
Authors
Keywords
-
Journal
PROSTATE CANCER AND PROSTATIC DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-04-14
DOI
10.1038/s41391-023-00668-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer
- (2022) Matthew R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trends in Incidence of Metastatic Prostate Cancer in the US
- (2022) Mihir M. Desai et al. JAMA Network Open
- Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
- (2021) Fred Saad et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate
- (2021) Scott T. Tagawa et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial
- (2021) Hannah L. Rush et al. JOURNAL OF CLINICAL ONCOLOGY
- Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP
- (2021) Martin R. Stockler et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study
- (2020) Arnulf Stenzl et al. EUROPEAN UROLOGY
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
- (2020) Philip Cornford et al. EUROPEAN UROLOGY
- Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity — United States, 2001–2017
- (2020) David A. Siegel et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial
- (2019) Karim Fizazi et al. LANCET ONCOLOGY
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
- (2019) Ian D. Davis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
- (2019) Kim N. Chi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
- (2019) Neeraj Agarwal et al. LANCET ONCOLOGY
- Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
- (2018) M R Sydes et al. ANNALS OF ONCOLOGY
- Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
- (2018) Kim N Chi et al. LANCET ONCOLOGY
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation
- (2015) L. Shamseer et al. BMJ-British Medical Journal
- Prognostic value of changes in quality of life scores in prostate cancer
- (2013) Digant Gupta et al. BMC Urology
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
- (2011) M. Herdman et al. QUALITY OF LIFE RESEARCH
- An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer
- (2008) George van Andel et al. EUROPEAN JOURNAL OF CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search